← Back

Amphastar P

Amphastar Pharmaceuticals, Inc. is a bio-pharmaceutical company that develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. Its products include BAQSIMI for severe hypoglycemia, Primatene MIST for intermittent asthma, Glucagon injection, Enoxaparin, and REXTOVY and Naloxone for opioid overdose. The company also offers diagnostic and emergency products such as Cortrosyn, Amphadase, Epinephrine injection, Lidocaine products, Phytonadione injection, and emergency syringes. In addition, it provides Albuterol sulfate inhalation aerosol, Iron sucrose injection, Teriparatide injection, Ipratropium Bromide HFA inhalation aerosol, and active pharmaceutical ingredient (API) products including Recombinant Human Insulin and porcine insulin API. Founded in 1996, Amphastar is headquartered in Rancho Cucamonga, California.

Price · split & dividend adjusted
News & notes moving AMPH
United States
AMPH▲

ANI Pharmaceuticals Leads Q2 Revenue Growth But Guides Weakest

ANI Pharmaceuticals reported second-quarter revenues of $266 million, up 25.9% year on year, beating analysts' expectations by 2.4%, but its full-year revenue guidance slightly missed estimates, making it the weakest guidance update among the four generic pharmaceuticals stocks tracked. The group as a whole beat consensus revenue estimates by 2.6%, with Amphastar Pharmaceuticals posting revenues of $183.9 million, up 5.4% year on year and beating expectations by 2%, while Viatris reported revenues of $3.76 billion, up 4.9% year on year and exceeding expectations by 2.2%, and Amneal reported revenues of $796.2 million, up 9.9% year on year and beating expectations by 3.6%. Despite the strong revenue performance, share prices of the four companies have fallen an average of 5.6% since their latest earnings results, with ANI Pharmaceuticals down 9.1% to $75.12, Viatris down 7.6% to $16.32, Amneal down 8.3% to $17.52, and Amphastar up 2.3% to $20.28.
ANIP ▼AMPH ▲AMRX ▼VTRS ▼
ANIP · Capital · Negative Q2 revenue beat but full-year guidance missed, stock fell 9.1%.
AMPH · Capital · Positive Q2 revenue beat expectations and stock rose 2.3%.
AMRX · Capital · Negative Q2 revenue beat but stock fell 8.3% on guidance concerns.
VTRS · Capital · Negative Q2 revenue beat but stock fell 7.6% on guidance concerns.
Read original ↗
Yahoo Finance·50dRead more →
United States
AMPH▼

Amphastar expects $2M-$3M quarterly IMS remediation costs, maintains 2026 sales growth outlook

Amphastar Pharmaceuticals anticipates $2 million to $3 million per quarter in additional expenses for several quarters due to remediation efforts at its IMS subsidiary, which recently received an FDA warning letter, while maintaining its overall corporate sales growth guidance of mid-single digit to high single-digit for 2026. The warning letter does not require IMS to stop manufacturing or distributing products, and management does not expect a material adverse effect on overall business operations. BAQSIMI generated $178.3 million in net sales, exceeding the $175 million threshold and triggering a first milestone payment to Lilly, with a milestone-triggering contract year and a $100 million payment due in Q3 2026. Second-quarter revenue rose 5% to $183.9 million, driven by the launch of Ipratropium Bromide Inhalation with $8.4 million in sales, while BAQSIMI net sales decreased 3% to $45.5 million due to pricing and rebate dynamics. The company also accelerated share repurchases, buying back approximately $45 million in the quarter, and reported adjusted net income of $40.8 million, or $0.91 per share.
AMPH ▼LLY ▲
AMPH · Regulation · Negative FDA warning letter leads to remediation costs of $2M-$3M per quarter
AMPH · Capital · Positive Accelerated share repurchases of $45M in the quarter
LLY · Demand · Positive BAQSIMI sales trigger $100M milestone payment from Amphastar
Read original ↗
Seeking Alpha·59dRead more →
© 2026 MarketDXAsset